Intravitreal Aflibercept Injection for Macular Edema Due to Central Retinal Vein Occlusion

McIntosh, 2010, Natural history of central retinal vein occlusion: an evidence-based systematic review, Ophthalmology, 117, 1113, 10.1016/j.ophtha.2010.01.060 Wong, 2010, Clinical practice. Retinal-vein occlusion, N Engl J Med, 363, 2135, 10.1056/NEJMcp1003934 Central Vein Occlusion Study Group, 1995, Evaluation of grid pattern photocoagulation for macular edema in central vein occlusion: the Central Vein Occlusion Study Group M report, Ophthalmology, 102, 1425, 10.1016/S0161-6420(95)30849-4 Haller, 2011, Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion: twelve-month study results, Ophthalmology, 118, 2453, 10.1016/j.ophtha.2011.05.014 SCORE Study Research Group, 2009, Arch Ophthalmol, 127, 1101, 10.1001/archophthalmol.2009.234 Tao, 2010, Intravitreal bevacizumab vs triamcinolone acetonide for macular oedema due to central retinal vein occlusion, Eye (Lond), 24, 810, 10.1038/eye.2009.220 Pournaras, 2008, Regulation of retinal blood flow in health and disease, Prog Retin Eye Res, 27, 284, 10.1016/j.preteyeres.2008.02.002 Noma, 2011, Role of soluble vascular endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion, Br J Ophthalmol, 95, 788, 10.1136/bjo.2010.192468 Ferrara, 2004, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer, Nat Rev Drug Discov, 3, 391, 10.1038/nrd1381 Boyer, 2012, Vascular endothelial growth factor Trap-Eye for macular edema secondary to central retinal vein occlusion: six-month results of the phase 3 COPERNICUS Study, Ophthalmology, 119, 1024, 10.1016/j.ophtha.2012.01.042 Brown, 2013, Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study, Am J Ophthalmol, 155, 429, 10.1016/j.ajo.2012.09.026 Holz, 2013, VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study, Br J Ophthalmol, 97, 278, 10.1136/bjophthalmol-2012-301504 Brown, 2010, Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study, Ophthalmology, 117, 1124, 10.1016/j.ophtha.2010.02.022 Papadopoulos, 2012, Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab, Angiogenesis, 15, 171, 10.1007/s10456-011-9249-6 Heier, 2012, VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration, Ophthalmology, 119, 2537, 10.1016/j.ophtha.2012.09.006 Do, 2011, The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema, Ophthalmology, 118, 1819, 10.1016/j.ophtha.2011.02.018 Campochiaro, 2011, Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study, Ophthalmology, 118, 2041, 10.1016/j.ophtha.2011.02.038 Heier, 2012, Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial, Ophthalmology, 119, 802, 10.1016/j.ophtha.2011.12.005